Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657707 | 0.94 | HTR1A (0.59) | HTR1ADRD2HTR2ADRD4HRH3 | |
| SCHEMBL5655625 | 0.91 | ALDH1A1 (0.56) | HTR1ADRD2HTR2ADRD4ALDH1A1 | |
| SCHEMBL5657912 | 0.89 | HTR1A (0.50) | HTR1ADRD2DRD4HRH3ALDH1A1 | |
| SCHEMBL5659556 | 0.89 | HTR4 (0.43) | HTR1ADRD2HTR2AADRA1A | |
| SCHEMBL5657837 | 0.87 | HTR1A (0.56) | HTR1ADRD2HTR2ADRD4HRH3 | |
| SCHEMBL5655977 | 0.86 | HTR1A (0.41) | HTR1ADRD2HTR2AALDH1A1ADRA1A | |
| SCHEMBL5659379 | 0.85 | LMNA (0.44) | HTR1ADRD4ALDH1A1ADRA1DADRA1A | |
| SCHEMBL5656351 | 0.84 | HTR1A (0.57) | HTR1ADRD2HTR2AHRH3ALDH1A1 | |
| SCHEMBL5657181 | 0.83 | OPRM1 (0.54) | HTR1ADRD2HTR2ADRD4HRH3 | |
| SCHEMBL5656672 | 0.83 | HTR1A (0.57) | HTR1ADRD2DRD4ALDH1A1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | claimed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | HTR1A 8/4885DRD2 73/4885HTR2A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.